Skip to main content
. 2019 Dec 12;12(1):1690959. doi: 10.1080/19420862.2019.1690959

Figure 5.

Figure 5.

CDC activity of IgG and DuetMab combinations targeting distinct or overlapping epitopes. (a–c) CDC activity of QD6 IgG and cetuximab IgG alone or in combination (a), GA201 IgG and cetuximab IgG alone or in combination (b), and QD6 IgG and GA201 alone or in combination (c) against HCC827 cells at a final serum concentration of 10% (vol/vol). (d–f) CDC activity of QD6/NMGC DuetMab and cetuximab/NMGC DuetMab alone or in combination (d), GA201/NMGC DuetMab and cetuximab/NMGC DuetMab alone or in combination (e), and QD6/NMGC DuetMab and GA201/NMGC DuetMab alone or in combination (f) against HCC827 cells at a final serum concentration of 10% (vol/vol). (g–i) CDC activity of trastuzumab IgG and pertuzumab IgG alone or in combination (g), trastuzumab IgG and B1D2 IgG alone or in combination (h), and pertuzumab IgG and B1D2 IgG alone or in combination (i) against BT474 cells at a final serum concentration of 5% (vol/vol). (j–l) CDC activity of trastuzumab/NMGC DuetMab and pertuzumab/NMGC DuetMab alone or in combination (j), trastuzumab/NMGC DuetMab and B1D2/NMGC DuetMab alone or in combination (k), and pertuzumab/NMGC DuetMab and B1D2/NMGC DuetMab alone or in combination (l) against BT474 cells at a final serum concentration of 5% (vol/vol). NMGC was used as an isotype control. Each point represents the mean values of triplicate wells, and the standard error of the mean is represented by error bars.